G 
Guanze Medical Information Industry (Holding) Co 2427.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
2.13
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥88.4m
FY2019FY2025
Net income
−CN¥29.7m
FY2019FY2025
Free cash flow
−CN¥9.2m
FY2019FY2025
Shareholders' equity
CN¥231.4m
FY2019FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | CN¥88.4m | CN¥132.2m | CN¥132.5m | CN¥150.4m | CN¥179.2m | CN¥156.6m | CN¥119.6m |
| Gross profit | CN¥22.1m | CN¥53.3m | CN¥72.5m | CN¥68.8m | CN¥64.3m | CN¥52.3m | CN¥39.4m |
| Research and development | CN¥5.8m | CN¥3.5m | CN¥1.3m | CN¥460,209 | CN¥336,241 | CN¥1.0m | — |
| Operating income | −CN¥30.9m | CN¥22.9m | CN¥33.5m | CN¥26.3m | CN¥28.6m | CN¥33.8m | CN¥25.2m |
| Net income | −CN¥29.7m | CN¥14.6m | CN¥23.4m | CN¥15.2m | CN¥19.5m | CN¥24.7m | CN¥19.0m |
| Diluted earnings per share | -0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Total assets | CN¥270.7m | CN¥304.2m | CN¥265.3m | CN¥278.3m | CN¥173.3m | CN¥130.7m | CN¥115.4m |
| Cash and short-term investments | — | CN¥28.2m | CN¥58.0m | CN¥24.9m | CN¥17.2m | CN¥4.7m | CN¥5.5m |
| Total liabilities | CN¥38.4m | CN¥44.8m | CN¥36.6m | CN¥57.4m | CN¥35.4m | CN¥47.1m | CN¥52.3m |
| Debt | — | CN¥17.9m | CN¥18.3m | CN¥21.8m | CN¥130,761 | CN¥3.2m | — |
| Shareholders' equity | CN¥231.4m | CN¥259.3m | CN¥228.7m | CN¥220.9m | CN¥137.9m | CN¥83.6m | CN¥63.1m |
| Shares outstanding | 950m | 950m | 950m | 950m | 950m | 950m | 950m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥10.4m | CN¥18.2m | CN¥7.5m | CN¥7.9m | CN¥2.6m | CN¥23.9m | CN¥4.7m |
| Capital spending | −CN¥19.5m | −CN¥24.7m | −CN¥6.2m | −CN¥7.9m | −CN¥6.7m | −CN¥12.2m | −CN¥8.3m |
| Free cash flow | −CN¥9.2m | −CN¥6.5m | CN¥1.3m | −CN¥11,888 | −CN¥4.0m | CN¥11.7m | −CN¥3.7m |
| Dividends paid | — | −CN¥15.4m | −CN¥15.5m | — | −CN¥390,583 | — | — |
Latest quarters
By quarter end
| Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 | Jun 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥56.6m | CN¥31.9m | CN¥98.2m | CN¥34.0m | CN¥69.3m | CN¥74.4m | CN¥78.5m | CN¥83.7m |
| Gross profit | CN¥8.7m | CN¥13.4m | CN¥34.7m | CN¥18.6m | CN¥35.8m | CN¥43.2m | CN¥41.4m | CN¥33.6m |
| Operating income | −CN¥35.7m | CN¥4.9m | CN¥20.3m | CN¥2.6m | CN¥13.8m | CN¥23.1m | CN¥8.8m | CN¥18.8m |
| Net income | −CN¥33.1m | CN¥3.4m | CN¥14.7m | −CN¥135,855 | CN¥9.9m | CN¥15.9m | CN¥2.6m | CN¥13.0m |
| Diluted earnings per share | -0.03 | 0.00 | 0.02 | -0.00 | 0.01 | 0.02 | 0.00 | 0.01 |
| Cash from operations | — | CN¥15.0m | CN¥18.0m | — | CN¥7.0m | — | CN¥11.0m | −CN¥1.0m |
| Capital spending | — | −CN¥6.0m | −CN¥24.0m | −CN¥3.0m | −CN¥6.0m | −CN¥5.0m | −CN¥4.0m | −CN¥3.0m |
| Free cash flow | — | CN¥9.0m | −CN¥6.0m | — | CN¥1.0m | — | CN¥7.0m | −CN¥4.0m |
| Total assets | CN¥270.7m | CN¥305.1m | CN¥258.3m | CN¥235.0m | CN¥265.3m | CN¥308.9m | CN¥327.7m | CN¥197.0m |
| Cash and short-term investments | — | CN¥34.0m | CN¥24.0m | CN¥27.9m | CN¥58.0m | — | CN¥29.4m | CN¥12.7m |
| Debt | — | CN¥15.0m | CN¥15.2m | CN¥15.9m | CN¥18.3m | — | CN¥25.6m | CN¥110,382 |
| Shareholders' equity | CN¥231.4m | CN¥263.3m | CN¥220.2m | CN¥204.8m | CN¥228.7m | CN¥257.8m | CN¥260.1m | CN¥150.9m |
Financial ratios
Data as of 24 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Gross margin | 25.0% | 40.3% | 54.7% | 45.7% | 35.9% | 33.4% | — |
| Operating margin | -34.9% | 17.3% | 25.3% | 17.5% | 15.9% | 21.6% | — |
| Net margin | -33.6% | 11.0% | 17.7% | 10.1% | 10.9% | 15.7% | — |
| Return on equity | -12.8% | 6.6% | 10.2% | 6.9% | 14.1% | 29.5% | — |
| Return on assets | -11.0% | 5.7% | 8.8% | 5.5% | 11.2% | 18.9% | — |
| Free cash flow yield | 0.4% | 0.8% | 0.3% | 0.4% | — | — | — |
| Revenue growth | -43.2% | -0.2% | -11.9% | -16.1% | 14.4% | 31.0% | — |
| Earnings growth | -272.7% | -37.6% | 53.6% | -21.8% | -21.0% | 30.1% | — |
| Current ratio | 5.61x | 5.64x | 6.51x | 4.38x | 4.20x | 2.44x | — |
| Debt to equity | — | 0.07x | 0.08x | 0.10x | 0.00x | 0.04x | 0.00x |
| Equity ratio | 85.5% | 85.3% | 86.2% | 79.4% | 79.6% | 64.0% | — |
| Interest coverage | -59.34x | 37.74x | 46.87x | 968.53x | 820.83x | 1421.14x | — |
| R&D as a share of sales | 6.5% | 2.6% | 1.0% | 0.3% | 0.2% | 0.6% | — |
| Buybacks as a share of market value | 0.0% | 0.0% | 0.0% | — | — | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -16.2% | -10.8% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 34.2% | 43.0% | 39.7% | — |
| Operating margin | -3.6% | 10.3% | 13.6% | — |
| Net margin | -6.8% | 4.7% | 8.1% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Price to earnings | -14.7 | 18.9 | 25.0 | 22.0 |
| Price to sales | 4.9 | 2.1 | 4.4 | 2.2 |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years. Last went ex-dividend on 4 Jun 2024.
| FY2024 | FY2023 | |
|---|---|---|
| Paid in the year | 0.021 | 0.021 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.